Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab
暂无分享,去创建一个
É. Remenár | A. Ladányi | J. Lövey | E. Toth | M. Gődény | Bence Kapuvári | K. Horváth | E. Papp | E. Tóth
[1] É. Remenár,et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] R. Orecchia,et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] S. Rottey,et al. TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)? , 2017, Head and Neck Pathology.
[4] V. Budach,et al. The PD‐1/PD‐L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK‐ROG) , 2017, International journal of cancer.
[5] Tuan Bui,et al. Multiparametric immune profiling in HPV- oral squamous cell cancer. , 2017, JCI insight.
[6] A. Psyrri,et al. p16, HPV, and Cetuximab: What Is the Evidence? , 2017, The oncologist.
[7] R. Ferris,et al. Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients , 2017, Cancer Immunology Research.
[8] Kelvin K. W. Chan,et al. Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review , 2017, Journal of Otolaryngology - Head & Neck Surgery.
[9] E. Richardsen,et al. Assessing PDL‐1 and PD‐1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach , 2017, Clinical lung cancer.
[10] P. Fournel,et al. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics , 2016, Oncotarget.
[11] P. Fournel,et al. Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. , 2016, American journal of clinical pathology.
[12] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[13] Xinxiang Li,et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer , 2016, Molecular Cancer.
[14] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[15] R. Muschel,et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma , 2016, Oncotarget.
[16] R. Ferris,et al. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients , 2016, Clinical Cancer Research.
[17] F. Penault-Llorca,et al. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer , 2016, International journal of cancer.
[18] Eva Negri,et al. Laryngeal cancer mortality trends in European countries , 2016, International journal of cancer.
[19] J. Carles,et al. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. , 2016, International journal of radiation oncology, biology, physics.
[20] C. Denkert,et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma , 2015, Oncotarget.
[21] S. Hahn,et al. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis , 2015, Cancer research and treatment : official journal of Korean Cancer Association.
[22] A. Ladányi,et al. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma , 2015, Pigment cell & melanoma research.
[23] R. Seethala,et al. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients , 2015, Cancer Immunology Research.
[24] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[25] I. Weissman,et al. Macrophages are critical effectors of antibody therapies for cancer , 2015, mAbs.
[26] R. Ferris,et al. Immune biomarkers of anti-EGFR monoclonal antibody therapy. , 2015 .
[27] Kevin P. White,et al. Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.
[28] L. Ding,et al. Accumulation of CD208⁺ mature dendritic cells does not correlate with survival time in oral squamous cell carcinoma patients. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[29] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] F. Penault-Llorca,et al. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] M. Rusan,et al. The interplay between HPV and host immunity in head and neck squamous cell carcinoma , 2014, International journal of cancer.
[32] D. Douek,et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.
[33] I. Çelik,et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. , 2014 .
[34] P. Kubes,et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. , 2014, The Journal of clinical investigation.
[35] M. Fresno,et al. p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. , 2014, Oral Oncology.
[36] C. Rödel,et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer , 2014, British Journal of Cancer.
[37] E. King,et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer , 2013, British Journal of Cancer.
[38] A. Argiris. Current status and future directions in induction chemotherapy for head and neck cancer. , 2013, Critical reviews in oncology/hematology.
[39] T. Nyberg,et al. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. , 2013, European journal of cancer.
[40] W. Gillanders,et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer , 2013, Breast Cancer Research and Treatment.
[41] J. Taube,et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.
[42] R. Ferris,et al. Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients , 2013, Clinical Cancer Research.
[43] L. Zitvogel,et al. Trial watch , 2012, Nature Reviews Cancer.
[44] C. Haymaker,et al. PD-1 and BTLA and CD8+ T-cell “exhaustion” in cancer , 2012, Oncoimmunology.
[45] H. Johansson,et al. Tumor Infiltrating CD8+ and Foxp3+ Lymphocytes Correlate to Clinical Outcome and Human Papillomavirus (HPV) Status in Tonsillar Cancer , 2012, PloS one.
[46] Xiaodong Li,et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer , 2012, Cancer Immunology, Immunotherapy.
[47] É. Remenár,et al. 8533 POSTER First Results of an Uncontrolled, Phase II Trial of Induction Chemotherapy With Cetuximab and Docetaxel-Cisplatin-5FU Followed by Cetuximab+Radiotherapy in the Responders in Locally Advanced Resectable Squamous Cell Cancer of the Head and Neck , 2011 .
[48] J. Tímár,et al. Prognostic impact of B-cell density in cutaneous melanoma , 2011, Cancer Immunology, Immunotherapy.
[49] R. Ferris,et al. Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity , 2011, Immunologic research.
[50] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[51] C. Denkert,et al. Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy , 2011, Seminars in Immunopathology.
[52] Laurence Zitvogel,et al. Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.
[53] S. Rosenberg,et al. Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells , 2010, Journal of immunotherapy.
[54] Soldano Ferrone,et al. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] C. la Vecchia,et al. The oral cancer epidemic in central and eastern Europe , 2010, International journal of cancer.
[56] I. Salmon,et al. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients , 2010, BMC Cancer.
[57] J. Tímár,et al. FOXP3+ Cell Density in Primary Tumor Has No Prognostic Impact in Patients with Cutaneous Malignant Melanoma , 2010, Pathology & Oncology Research.
[58] S. Rosenberg,et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.
[59] T. Dønnem,et al. Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[60] L. Zitvogel,et al. The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.
[61] T. Gorlia,et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.
[62] J. Tímár,et al. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma , 2007, Pathology & Oncology Research.
[63] J. Cheville,et al. PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.
[64] J. Tímár,et al. Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor , 2007, Cancer Immunology, Immunotherapy.
[65] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[66] E. Tartour,et al. Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers , 2006, Clinical Cancer Research.
[67] L. Zitvogel,et al. Trial watch , 2012, Oncoimmunology.
[68] B. Döme,et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Tímár,et al. T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant Melanoma , 2004, Clinical Cancer Research.
[70] R. Day,et al. The number of intratumoral dendritic cells and ζ‐chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma , 2001, Cancer.
[71] Mechthild Krause,et al. CD8+ tumour‐infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK‐ROG) , 2016, International journal of cancer.
[72] T. O’Toole,et al. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. , 2014, Methods.
[73] Patrice Ravel,et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.
[74] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] M. Kloor,et al. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. , 2009, Cancer immunity.